What Is The Current and Historic Market Size Analysis Of The Pancreatic Cancer Diagnostic Market?
The pancreatic cancer diagnostic market has seen considerable growth due to a variety of factors.
•In recent times, the pancreatic cancer diagnostic market has been expanding rapidly. The market, valued at $4.24 billion in 2024, is predicted to increase to $4.55 billion in 2025, experiencing a compound annual growth rate (CAGR) of 7.2%.
The progress seen in the past can be linked to advancements in genomic and molecular profiling, enhancements in chemotherapy procedures, refinements in radiation therapy, research advancements in pancreatic cancer genetics, public awareness drives, and initiatives towards early detection of the disease.
What Are The Predictions for The Pancreatic Cancer Diagnostic Market Size In The Coming Years?
The pancreatic cancer diagnostic market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for pancreatic cancer diagnostics is likely to witness impressive growth in the upcoming years. Predictions indicate that the market value will reach $6.38 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.8%.
Factors contributing to this growth during the projected period include improvements in liquid biopsy, targeted treatments, the use of AI in diagnostics, personalized medication strategies, preclinical discovery of biomarkers, and the use of neoadjuvant therapies. Other noteworthy developments expected to shape the market in the predicted period are research in the field of immunotherapy, advanced imaging technologies, surgical breakthroughs, joint global research efforts, and the incorporation of large data analytics.
Which Drivers Are Accelerating Growth In The Pancreatic Cancer Diagnostic Market?
The escalating incidence of pancreatic cancer is predicted to fuel expansion in the pancreatic cancer diagnostic market. This type of cancer involves the malignant transformation of pancreatic cells. Factors like smoking, diabetes, chronic pancreatitis, familial pancreatic cancer history, pancreatic inflammation, and some genetic ailments primarily contribute to its surge. Diagnostic evaluation is essential in pancreatic cancer to steer treatment plans, ascertain cancer stage, recognize tumor details, and adjust treatment strategies for improved results and better patient handling. As per the American Society of Clinical Oncology, a professional organization based in the United States, they forecast that 64,050 people (33,130 males and 30,920 females) will get diagnosed with pancreatic cancer in 2023. Pancreatic cancer is the eighth most common cancer among women and tenth amongst men. The rate of new pancreatic cancer cases has increased approximately 1% annually in both genders. Hence, the escalating incidence of pancreatic cancer is contributing to the expansion of the pancreatic cancer diagnostic market.
What Are The Core Segments Of The Global Pancreatic Cancer Diagnostic Market?
The pancreatic cancer diagnostic market covered in this report is segmented –
1) By Product: Instruments, Consumables, Services
2) By Treatment: Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy
3) By Cancer Type: Exocrine, Adenocarcinoma, Squamous Cell Carcinoma, Adenosquamous Carcinoma, Colloid Carcinoma, Endocrine
4) By Test Type: Imaging Test, Biopsy, Blood Test, Genomic Test, Other Test Types
5) By End-User: Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Instruments: Imaging Systems, Biopsy Devices, Endoscopy Equipment
2) By Consumables: Reagents, Biopsy Needles, Assay Kits
3) By Services: Diagnostic Testing Services, Laboratory Services, Consulting Services
Pre-Book The Pancreatic Cancer Diagnostic Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Trends Are Reshaping The Pancreatic Cancer Diagnostic Market Size?
Greater product innovation is trending within the pancreatic cancer diagnostics market. To maintain their market position, pancreatic cancer diagnostics companies are implementing innovative solutions. A primary example of this occurred in March 2023, when the biopharmaceutical company Prestige Biopharma Limited, based in Singapore, introduced the groundbreaking PAUF-detecting diagnostic kit to the market. PAUF, or Pancreatic Adenocarcinoma Upregulated Factor, is a specific biomarker linked to early metastasis and overexpression in a majority (around 80%) of pancreatic cancer cases. This cutting-edge diagnostic technique has been proven to accurately identify PAUF with high sensitivity and specificity. Preliminary research indicates that the PAUF expression level in pancreatic cancer patients' blood plasma is almost 1.9 times the level found in the blood plasma of healthy people, as reported by Prestige Biopharma's Innovative Discovery Center (IDC).
Who Are the Key Players in the Pancreatic Cancer Diagnostic Market?
Major companies operating in the pancreatic cancer diagnostic market include:
• Pfizer Inc.
• Hitachi Medical Corporation
• F. Hoffmann-La Roche AG
• Novartis AG
• Bristol-Myers Squibb Company
• Thermo Fisher Scientific Inc.
• AstraZeneca plc
• Abbott Laboratories Inc.
• Danaher Corporation
• Siemens Healthcare GmbH
• FUJIFILM Corporation
• Becton Dickinson and Company
• Koninklijke Philips N.V.
• GE Healthcare Bio Sciences AB
• Laboratory Corporation of America Holdings
• Agilent Technologies Inc.
• Illumina Inc.
• Qiagen Inc.
• Myriad Genetics Inc.
• Canon Medical Systems Corporation
• Biological Dynamics Inc.
• Berg LLC
• Abcodia Ltd.
• Acobiom
• Amplified Sciences LLC
• Avant Diagnostics Inc.
• Axim Biotechnologies Inc.
• Alaunus Biosciences Inc.
• Advanced Marker Discovery SL
• Anixa Diagnostics Corporation
What are the Regional Insights into the Pancreatic Cancer Diagnostic Market?
North America was the largest region in the pancreatic cancer diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pancreatic cancer diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
